OSSM-007 is under clinical development by Ossium Health and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OSSM-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OSSM-007 is under investigation for the prophylaxis of acute graft versus host disease and asthma. It is administered through parenteral route. The therapeutic candidate comprises of interferon gamma (IFNg)-primed human bone marrow-derived mesenchymal stromal cells.
Ossium Health overview
Ossium Health is a bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation that develops and manufactures cell therapy products that cure leukemia and other blood cancers, improve organ transplantation, treat radiation poisoning, and heal tissue damage. Ossium Health is headquartered in San Francisco, California, the US.
For a complete picture of OSSM-007’s drug-specific PTSR and LoA scores, buy the report here.